Articles tagged "Induction therapy"

2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
V. Gurram, K. Gurung, G. Orlando, A. Farney, J. Rogers, C. Jay, W. Doares, S. Kaczmorski, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, R. Stratta
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…
2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
M. Colladant¹, J. Lion², P. Saas³, S. Perruche³, D. Ducloux¹, N. Mooney², J. Bamoulid¹
¹Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, ²Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, ³INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
K. Lang¹, J. Shulte¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, J. Leventhal²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…
2020 American Transplant Congress
Comparative Study between ATG and Grafalon as Induction Agent in Renal Transplant Recipient
L. K. Das, P. Paudyal, S. Shrestha, B. Shahi, A. Pandey, R. Verma, P. Chandra Shrestha
Kidney and Liver Transplant, Shahid Dharmabhakta National Transplant Center, Kathmandu, Nepal
*Purpose: Renal transplantation (Rtx) remains the most effective treatment for of end-stage renal disease (ESRD). The development of induction therapy has significantly reduced the incidence…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
2020 American Transplant Congress
Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age
L. Wang, J. Motter, S. Bae, D. Segev, M. McAdams DeMarco
Johns Hopkins University, Baltimore, MD
*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to…
2020 American Transplant Congress
Efficacy and Safety of Single-Dose Rabbit Anti-Thymocyte Globulin versus Basiliximab Induction among Pediatric Kidney Transplant Recipients
L. Porini Custodio, S. Stopa Martins, L. Almeida Viana, M. Pontello Cristelli, M. Rika Nakamura, H. Tedesco-Silva, J. Medina-Pestana
Hospital do Rim, Sao Paulo, Brazil
*Purpose: Induction therapy is a standard component of kidney transplant immunosuppression protocols. However, in the pediatric population, there are still uncertainties about the ideal induction…
2020 American Transplant Congress
Safety and Efficacy of Low Dose Rabbit Antithymocyte Globulin in Pediatric Renal Transplant Recipients
V. K. Sigurjonsdottir¹, L. Maestretti¹, A. McGrath¹, A. Gallo², W. Concepcion², P. Grimm¹, A. Chaudhuri¹
¹Pediatric Nephrology, Stanford University, Stanford, CA, ²Surgery - Multi-Organ Transplantation, Stanford University, Stanford, CA
*Purpose: Currently there is no consensus among pediatric kidney transplant centers regarding the use and regimen for immunosuppressive induction therapy.The safety and effectiveness of reduced…
2020 American Transplant Congress
Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation
A. I. Ingemi¹, O. F. Bangash¹, S. McCoy¹, L. Hulse², J. Colonna¹, H. Sadr¹, S. Sutton¹, M. Coleman¹, T. Wilson¹, T. R. McCune¹
¹Sentara Norfolk General Hospital, Norfolk, VA, ²Children's Hospital of the King's Daughters, Norfolk, VA
*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in…
2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
T. Shaker¹, G. Larrieux¹, S. Jackson², S. Riad³, T. Pruett¹, T. Leventhal⁴
¹Surgery, Division of Transplantation, University of Minnesota, Minneapolis, MN, ²M Health Fairview, Minneapolis, MN, ³Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, ⁴Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…

« Previous Page
1
…
4
5
6
7
8
…
31
Next Page »